Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813861 | 0.90 | CES2 (0.36) | CES2GAATDP2NPSR1KDM4E | |
| SCHEMBL6488759 | 0.78 | CES2 (0.43) | CES2KDM4ERAB9AL3MBTL1 | |
| SCHEMBL8343767 | 0.65 | CES2 (0.39) | CES2GAATDP2NPSR1PPARG | |
| SCHEMBL6477074 | 0.65 | CES2 (0.33) | CES2TDP2L3MBTL1 | |
| SCHEMBL6289358 | 0.64 | CES2 (0.38) | CES2GAATDP2NPSR1PPARG | |
| SCHEMBL6477887 | 0.63 | CES2 (0.42) | CES2GAATDP2NPSR1KDM4E | |
| SCHEMBL31424239 | 0.59 | ALDH1A1 (0.62) | CES2GAAKDM4EL3MBTL1 | |
| SCHEMBL8344423 | 0.59 | GAA (0.41) | CES2GAAPPARGL3MBTL1 | |
| SCHEMBL30020109 | 0.58 | GAA (0.54) | CES2GAANPSR1KDM4EL3MBTL1 | |
| SCHEMBL8344771 | 0.58 | GAA (0.41) | CES2GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | claimed |
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | CES2 2239/4885GAA 816/4885TDP2 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.